SEC Form 4 · accession 0001171843-16-007779
Xenon Pharmaceuticals Inc. · XENE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James R. Empfield
Officer — SVP, Drug Discovery
Period of report
Feb 8, 2016
Accepted (ET)
Feb 9, 2016 · 6:15 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001582313
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $6.76 | Feb 8, 2016 | A | 40,000 | A | — | Feb 7, 2026 | Common Shares | 40,000 | 40,000 | D |
Explanation of responses
- F1Vesting 25% on February 8, 2017, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month.